Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
05/2010
05/18/2010US7718673 Heterocyclic amides such as beta-(((1-(4-((4,5-dihydro-1H-imidazol-2-yl)amino)-1-oxobutyl)-4 -piperidinyl)carbonyl)amino) -,(beta 3S)-3-quinolinepropanoic acid, used as antagonists for cellular adhesion molecules
05/18/2010US7718672 Substituted tetrahydroisoquinoline compounds, methods of making, and their use
05/18/2010US7718671 Substituted small-molecule arylthiourea compounds are potent and/or selective inhibitors of viral replication in vivo, particularly Hepatitis C virus replication; e.g., 1-(3-benzyloxy)phenylthiourea; side effect reduction
05/18/2010US7718670 antagonists of M3 muscarinic receptors; N-(1-Azabicyclo[2.2.2]oct-3-yl)-2-hydroxy-2,2-dithien-2-ylacetamide; respiratory disorders, urological disorders, gastrointestinal disorders, cardiovascular disorders; reaction with organometallic derivative
05/18/2010US7718669 Triazolopyridine derivatives as inhibitors of lipases and phospholipases
05/18/2010US7718668 phosphodiesterase inhibitor; drug for respiratory system disorders
05/18/2010US7718667 Fused aminopiperidines as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
05/18/2010US7718666 Pyrido [2,1-a] isoquinoline derivatives
05/18/2010US7718665 10-(o-Hydroxyphenyl)--3a,4,9,10-tetrahydro-2-alkyl-2,9,10a-triazacyclopenty[b]fluorene-1,3-diones or the corresponding 2,10a-diaza-9 oxafluorenediones or 1,10a-diaza-9-thiafluorenediones; antiproliferative, apoptosis-inducing agents; treating color cancer
05/18/2010US7718664 Anti-itching agent
05/18/2010US7718663 Quinazoline derivatives and medicaments
05/18/2010US7718662 Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase
05/18/2010US7718661 E.g., 4-Difluoro-5-[4-trifluoromethyl-2-(4-trifluoromethyl-phenyl)-imidazo[1,5-a]pyrimidin-8-ylethynyl]-benzenesulfonamide; 4-[4-Difluoromethyl-2-(4-trifluoromethyl-phenyl)-imidazo[1,5-a]pyrimidin-8-ylethynyl]-benzenesulfonamide; metabotropic glutamate receptor antagonists; nervous system disorders
05/18/2010US7718660 Inhibitors of folic acid-dependent enzymes
05/18/2010US7718659 Coagulation factor Xa inhibitors; such as [4-(2-[1,4']-Bipiperidinyl-1'-yl-2-oxo-ethyl)-thiazol-2-yl]-4-chloro-benzamide
05/18/2010US7718658 Saturated ring with 2 nitrogens, 1 of which is 2-(o-(difluoromethyl)phenyl)quinazol-4-yl-substituted and the other is oxyalkanoyl-substituted; inhibitors of voltage-gated sodium channels and calcium channels; treating acute, chronic, neuropathic, or inflammatory pain
05/18/2010US7718657 Certain indanyl urea modulators of the cardiac sarcomere
05/18/2010US7718656 Nitrooxyderivatives of prostaglandin amides, e.g., N-(3-(nitrooxy)propyl) 1R-[1 alpha (Z),2 beta (R*),3 alpha ,5 alpha ]]-7-[3,5-dihydroxy-2-(3-hydroxy-5-phenylpentyl)cyclopentyl]-5-heptenamide; reduced side effects,wider pharmacological activity, enhanced tolerability, long-acting hypotensive activity
05/18/2010US7718655 formed via cyanuric chloride; for treatment of cancer and proliferative diseases
05/18/2010US7718654 Substituted pteridines for the treatment of inflammatory diseases
05/18/2010US7718653 Pyrimidine derivatives for inhibiting Eph receptors
05/18/2010US7718652 Substituted benzothiadiazinedioxide derivatives and methods of their use
05/18/2010US7718651 Inhibiting polymerization of FtsZ in a bacterium by contactng with 2,3-diphenyl-6-(ethoxycarbonylamino)-8-(4-(diethylamino)-1-methylbutylamino)pyrido[2,3-b]pyrazine, optionally linked to a permeability enhancer to allow the compound to cross the bacterium's cell envelope
05/18/2010US7718650 Piperazino or diazepino-substituted arylsulfonamides; obesity, type II diabetes and/or central nervous system disorders; 4-chloro-N-[5-(4-methyl-1,4-diazepan-1-yl)-2-nitrophenyl]benzenesulfonamide for example; Serotonin 5-HT6 receptor antagonist activity
05/18/2010US7718649 Physical states of a pharmaceutical drug substance
05/18/2010US7718648 Pyridobenzazepine compounds and methods for inhibiting mitotic progression
05/18/2010US7718647 5,6,7,8-Tetrahydro-4H-thieno[2,3-d]azepine and 4,4a,5,6,7,8-hexahydro-3H-1-thia-6-aza-cyclopenta[cd]azulene derivatives can be used to treat addiction, anxiety, depression and obesity
05/18/2010US7718646 Cyclohexyl(alkyl)propanolamines, preparation method and pharmaceutical compositions containing same
05/18/2010US7718645 4-[4-(4-Amino-5-oxo-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-6(5H)-yl)phenyl]cycloalkylalkyl nitriles, carboxy acids or esters, amides, e.g., a -cyclohexylacetonitrile; diglyceride acyltransferase inhibitors for treating type II diabetes and obesity
05/18/2010US7718644 Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof
05/18/2010US7718643 Pharmaceutical formulation
05/18/2010US7718642 Mixture with spermicide antiseptics and fungicide
05/18/2010US7718641 Pyrrolo [3,4-H] isoquinoline compounds and methods for modulating gated ion channels
05/18/2010US7718640 Methods and pharmaceutical compositions for reliable achievement of acceptable serum testosterone levels
05/18/2010US7718639 7-hydroxyepiandrosterone having neuroprotective activity
05/18/2010US7718638 Arresting the proliferation of undifferentiated cells and inducing their differentiation; anticancer agents; treating psoriasis, wrinkles, slack skin, dry skin, insufficient sebum secretion, autoimmune disorders, inflammatory diseases, renal osteodystrophy. and obesity; little, if any, calcemic activity
05/18/2010US7718637 Arresting the proliferation of undifferentiated cells and inducing their differentiation; anticancer agents; treating psoriasis, wrinkles, slack skin, dry skin, insufficient sebum secretion, autoimmune disorders, inflammatory diseases, renal osteodystrophy. and obesity; little, if any, calcemic activity
05/18/2010US7718636 Administering to a post menopausal woman an effective amount of 2-methylene -19-nor-20(S)-1 alpha ,25-dihydroxyvitamin D3
05/18/2010US7718635 cosmetic product comprising ursolic acid phosphate for delivery ursolic acid with improving solubility; treating skin disorder inflammation and melanin production
05/18/2010US7718634 Method of treatment using bisphosphonic acid
05/18/2010US7718633 Prodrugs of HIV protease inhibitors
05/18/2010US7718632 RNAi inhibition of alpha-ENaC expression
05/18/2010US7718631 For treating p53 containing cancer
05/18/2010US7718630 Using RNA interference to reduce notch ligand Delta protein expression; diagnosis and treatment of cell proliferative disorders
05/18/2010US7718629 double-stranded ribonucleic acid comprises a sense strand first sequence and an antisense strand second sequence; modified; as a biodrug for treating diseases caused by Eg5 expression; as anticarcinogenic agent for treating cancer; selectively and efficiently silence the Eg5 gene
05/18/2010US7718628 modified oligonucleotide for gene therapy; as antitumor agent, anticarcinogenic agent; Inhibiting synthesis and function; arresting cellular proliferation
05/18/2010US7718627 Plasmid comprising nucleotide sequences coding immunoglobulin complementary determining regions specific to tumor antigen (5T4); for use in delivering product and/or nucleotide sequences of interest to tumor; drug delivery
05/18/2010US7718625 Polynucleotides targeted against the extended 5′-UTR region of argininosuccinate synthase and uses thereof
05/18/2010US7718624 biodrug delivery a nucleic acid for treating bacterial infection or viral infection; reverse transcriptase enzyme inhibitor; sepsis, septic shock, encephalitis, meningitis, acute respiratory distress syndrome, severe acute respiratory syndrome, tuberculosis, lyme disease, HIV infection
05/18/2010US7718623 Immunostimulatory oligonucleotide that induces interferon alpha
05/18/2010US7718622 freezing dried biochemical conjugated immunomodulator comprising immunostimulatory polynucleotide sequence and plant Ragweed allergen; genetic vaccines
05/18/2010US7718621 Antibacterial activity; 4''-O-{3-[3-(3-Carboxy-1,4-dihydro-1-dimethylamino-4-oxo-6-quinolinyl)propylamino]propionyl}-6-O-methylerythromycin A
05/18/2010US7718619 Abuse-resistant amphetamine prodrugs
05/18/2010US7718614 Combination therapy of peptide vaccination and estramustine treatment
05/18/2010US7718609 Rapid acting and long acting insulin combination formulations
05/18/2010US7718417 recombinant yeast comprising one or more heterologous nucleic acid molecules encoding an enzyme that converts pyruvate and D-glyceraldehyde 3-phosphate to 1-deoxyxylose 5-phosphate and another that converts 1-deoxy-D-xylulose 5-phosphate to 2-C-methyl-D-erythritol 4-phosphate
05/18/2010US7718401 Expression of HIV polypeptides and production of virus-like particles
05/18/2010US7718394 Methods for diagnosis and monitoring of neurological disease by detection of an encephalotoxin
05/18/2010US7718385 Rapid screening for identifying acylfulvenes and analogs thereof with improved chemotherapeutic properties; oxidoreductases
05/18/2010US7718382 Method for identifying compounds for treatment of pain
05/18/2010US7718377 Insulin resistance curative and method of screening the same
05/18/2010US7718360 distilled cow urine containing mixture of benzoic acid, hexanoic acid and ammonia
05/18/2010US7718200 Plant extract mixtures and their uses
05/18/2010US7718197 Colonic purgative composition with soluble binding agent
05/18/2010US7718193 A block copolymer of a first block comprising a random copolymer temperature-responsive monomer of an N-alkylacrylamide and a pH-responsive monomer of an C2-C8 alkyl acrylate; anda second hydrophobic block; drug delivery devices; drugs/polymerconjugates; nanoparticles; micelles; diagnosis/medical/
05/18/2010US7718192 Tamper-resistant oral opioid agonist formulations
05/18/2010US7718191 Pharmaceutical product which is used to reduced or stop moderate or severe snoring
05/18/2010US7718190 Self forming, thermodynamically stable liposomes and their applications
05/18/2010US7718189 A liposomal aminoglycoside formulation comprising a liposome having a lipid bilayer encapsulating an aminoglycoside where the lipid bilayer comprises a neutral phospholipid and a sterol; anionic lipids-free;respiratory system disorders; cystic fibrosis; tissue-targeted therapy
05/18/2010US7718188 Contains polyisobutylene, a mineral oil and isopropyl myristate as pressure-sensitive adhesive agents; durability; stability; excellent adhesion; skin permeability; cost efficiency
05/18/2010US7718185 Inhibitors of melanocyte tyrosinase as topical skin lighteners
05/18/2010US7718178 Allergen formulation
05/18/2010US7718177 Antibodies directed to fragments of connective tissue growth factor (CTGF) polypeptide and methods and uses thereof
05/18/2010US7718163 Includes additive material on the surfaces of the carrier particles to promote the release of the active particles from the carrier particles on actuation of the inhaler; an inhalant includes crystalline milk sugar carrier,leucine additive and beclomethasone dipropionate inhalant
05/18/2010US7718162 Medicinal aerosol compositions with a functionalized polyethyleneglycol excipient
05/18/2010US7718161 Method for treating a motoneuron disorder
05/18/2010CA2585027C Process for the preparation of bisphosphonates
05/18/2010CA2574398C Powder inhaler featuring reduced compaction
05/18/2010CA2564367C Delta crystalline form of ivabradine chlorhydrate, process for its preparation and pharmaceutical compositions containing it
05/18/2010CA2555429C Stable injectable diclofenac compositions
05/18/2010CA2473205C Orodispersible pharmaceutical composition comprising perindopril
05/18/2010CA2472475C 17-hydroxy-4-aza-androstan-3-ones as androgen receptor modulators
05/18/2010CA2465247C Benzimidazoles and analogues and their use as protein kinases inhibitors
05/18/2010CA2455226C Compositions comprising an o/w emulsion containing conjugated linoleic acid
05/18/2010CA2439478C Carbamate compounds for use in preventing or treating movement disorders
05/18/2010CA2439475C Carbamate compounds for use in preventing or treating bipolar disorder
05/18/2010CA2438421C Process for the preparation of imidazole compounds
05/18/2010CA2437754C Tablets quickly disintegrated in oral cavity
05/18/2010CA2430508C Condensed purine derivatives as a1 adenosine receptor antagonists
05/18/2010CA2422371C Pyrazole compounds useful as protein kinase inhibitors
05/18/2010CA2422367C Pyrazole compounds useful as protein kinase inhibitors
05/18/2010CA2401498C New self emulsifying drug delivery system
05/18/2010CA2387536C Rate-controlled particles
05/18/2010CA2383357C Use of tosylchloramide(s) for treating diseases of the skin, mucous membranes, organs and tissues
05/18/2010CA2382465C Compositions and methods for modulating apoptosis in cells over-expressing bcl-2 family member proteins
05/18/2010CA2355716C Benzisoxazoles and phenones as .alpha.2-antagonists
05/18/2010CA2339667C Method of using tetracycline compounds to enhance interleukin-10 production
05/18/2010CA2338223C Viologen linked acridine based molecule and process for the preparation thereof
05/18/2010CA2304204C Quinoline-containing .alpha.-ketoamide cysteine and serine protease inhibitors
05/18/2010CA2296409C Agents comprising midkine or its inhibitor as active ingredient